Pharmacokinetics of Miltefosine in Children and Adults: Implications for the Treatment of Cutaneous Leishmaniasis in Colombia. View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2011-2015

ABSTRACT

The purpose of this study is to determine the pharmacokinetics of miltefosine in children and adults with cutaneous leishmaniasis in plasma and intracellularly, and its relation with the parasitologic response. The results will provide pharmacologic bases to optimize the use of miltefosine for the treatment of cutaneous leishmaniasis, and will provide the knowledge base to assess the impact of pharmacokinetic behavior in children and adults on the emergence of drug resistance. Detailed Description An open-label phase IV clinical trial of miltefosine, designed to evaluate intracellular and plasma drug pharmacokinetics in children and adults using a population pharmacokinetics design. Two study groups have been defined: 1) children 2-12 years of age (n=30) and 2) adults 18-60 years of age (n=30) with confirmed parasitological diagnosis of cutaneous leishmaniasis. The participants will receive supervised standard treatment with miltefosine: 1.8 - 2.5 mg/Kg of weight for 28 days. Miltefosine concentration will be determined in plasma and Peripheral Blood Mononuclear Cell (PBMCs), from 3 or 10ml peripheral blood samples in children and adults respectively. Sampling will be conducted pre-dosing at days 0,1,15 and 29 during treatment, and at months 1, 2, 3 and 6 post-treatment. A population pharmacokinetics analysis will be performed using a non-linear model of mixed effects with the software Nonlinear Mixed-effects Model (NONMEM), R and Piranha. Parasite burden will be determined by 7SLRNA Quantitative Polymerase Chain Reaction (qPCR) of Leishmania from swab samples of lesions and extralesional tissues before and at the end of treatment. The relationship between pharmacokinetics and parasite persistence/burden will be determined by correlation analysis and pharmacodynamic modeling. More... »

URL

https://clinicaltrials.gov/show/NCT01462500

Related SciGraph Publications

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3053", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "The purpose of this study is to determine the pharmacokinetics of miltefosine in children and adults with cutaneous leishmaniasis in plasma and intracellularly, and its relation with the parasitologic response. The results will provide pharmacologic bases to optimize the use of miltefosine for the treatment of cutaneous leishmaniasis, and will provide the knowledge base to assess the impact of pharmacokinetic behavior in children and adults on the emergence of drug resistance.\n\nDetailed Description\nAn open-label phase IV clinical trial of miltefosine, designed to evaluate intracellular and plasma drug pharmacokinetics in children and adults using a population pharmacokinetics design. Two study groups have been defined: 1) children 2-12 years of age (n=30) and 2) adults 18-60 years of age (n=30) with confirmed parasitological diagnosis of cutaneous leishmaniasis. The participants will receive supervised standard treatment with miltefosine: 1.8 - 2.5 mg/Kg of weight for 28 days. Miltefosine concentration will be determined in plasma and Peripheral Blood Mononuclear Cell (PBMCs), from 3 or 10ml peripheral blood samples in children and adults respectively. Sampling will be conducted pre-dosing at days 0,1,15 and 29 during treatment, and at months 1, 2, 3 and 6 post-treatment. A population pharmacokinetics analysis will be performed using a non-linear model of mixed effects with the software Nonlinear Mixed-effects Model (NONMEM), R and Piranha. Parasite burden will be determined by 7SLRNA Quantitative Polymerase Chain Reaction (qPCR) of Leishmania from swab samples of lesions and extralesional tissues before and at the end of treatment. The relationship between pharmacokinetics and parasite persistence/burden will be determined by correlation analysis and pharmacodynamic modeling.", 
    "endDate": "2015-12-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT01462500", 
    "keywords": [
      "pharmacokinetics", 
      "adult", 
      "implication", 
      "cutaneous leishmaniasis", 
      "child", 
      "plasma", 
      "relation", 
      "base", 
      "knowledge base", 
      "emergence", 
      "drug resistance", 
      "Phase IV clinical trial", 
      "drug pharmacokinetics", 
      "population pharmacokinetics", 
      "study group", 
      "age", 
      "diagnosis", 
      "standard treatment", 
      "weight", 
      "peripheral blood mononuclear cell", 
      "peripheral blood sample", 
      "sampling", 
      "post-treatment", 
      "mixed effect model", 
      "quantitative polymerase chain reaction", 
      "qPCR", 
      "Leishmania", 
      "sample", 
      "lesion", 
      "tissue", 
      "parasite", 
      "correlation analysis", 
      "pharmacodynamics"
    ], 
    "name": "Pharmacokinetics of Miltefosine in Children and Adults: Implications for the Treatment of Cutaneous Leishmaniasis in Colombia.", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT01462500"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:24", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00011.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.5650.6", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.418350.b", 
        "type": "Organization"
      }
    ], 
    "startDate": "2011-10-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "https://doi.org/10.1128/aac.00014-08", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014236737"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1517/17425255.4.9.1209", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021198914"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00431-006-0188-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035417123", 
          "https://doi.org/10.1007/s00431-006-0188-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00431-006-0188-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035417123", 
          "https://doi.org/10.1007/s00431-006-0188-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.trstmh.2006.02.010", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1054751293"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1128/aac.02198-16", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1062709537"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1371/journal.pntd.0005515", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084622300"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT01462500"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT01462500'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT01462500'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT01462500'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT01462500'


 

This table displays all metadata directly associated to this object as RDF triples.

73 TRIPLES      16 PREDICATES      55 URIs      42 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT01462500 schema:about anzsrc-for:3053
2 schema:description The purpose of this study is to determine the pharmacokinetics of miltefosine in children and adults with cutaneous leishmaniasis in plasma and intracellularly, and its relation with the parasitologic response. The results will provide pharmacologic bases to optimize the use of miltefosine for the treatment of cutaneous leishmaniasis, and will provide the knowledge base to assess the impact of pharmacokinetic behavior in children and adults on the emergence of drug resistance. Detailed Description An open-label phase IV clinical trial of miltefosine, designed to evaluate intracellular and plasma drug pharmacokinetics in children and adults using a population pharmacokinetics design. Two study groups have been defined: 1) children 2-12 years of age (n=30) and 2) adults 18-60 years of age (n=30) with confirmed parasitological diagnosis of cutaneous leishmaniasis. The participants will receive supervised standard treatment with miltefosine: 1.8 - 2.5 mg/Kg of weight for 28 days. Miltefosine concentration will be determined in plasma and Peripheral Blood Mononuclear Cell (PBMCs), from 3 or 10ml peripheral blood samples in children and adults respectively. Sampling will be conducted pre-dosing at days 0,1,15 and 29 during treatment, and at months 1, 2, 3 and 6 post-treatment. A population pharmacokinetics analysis will be performed using a non-linear model of mixed effects with the software Nonlinear Mixed-effects Model (NONMEM), R and Piranha. Parasite burden will be determined by 7SLRNA Quantitative Polymerase Chain Reaction (qPCR) of Leishmania from swab samples of lesions and extralesional tissues before and at the end of treatment. The relationship between pharmacokinetics and parasite persistence/burden will be determined by correlation analysis and pharmacodynamic modeling.
3 schema:endDate 2015-12-01T00:00:00Z
4 schema:keywords Leishmania
5 Phase IV clinical trial
6 adult
7 age
8 base
9 child
10 correlation analysis
11 cutaneous leishmaniasis
12 diagnosis
13 drug pharmacokinetics
14 drug resistance
15 emergence
16 implication
17 knowledge base
18 lesion
19 mixed effect model
20 parasite
21 peripheral blood mononuclear cell
22 peripheral blood sample
23 pharmacodynamics
24 pharmacokinetics
25 plasma
26 population pharmacokinetics
27 post-treatment
28 qPCR
29 quantitative polymerase chain reaction
30 relation
31 sample
32 sampling
33 standard treatment
34 study group
35 tissue
36 weight
37 schema:name Pharmacokinetics of Miltefosine in Children and Adults: Implications for the Treatment of Cutaneous Leishmaniasis in Colombia.
38 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT01462500
39 schema:sdDatePublished 2019-03-07T15:24
40 schema:sdLicense https://scigraph.springernature.com/explorer/license/
41 schema:sdPublisher Naed2a69d651f4e218f18eaed018bd5a0
42 schema:sponsor https://www.grid.ac/institutes/grid.418350.b
43 https://www.grid.ac/institutes/grid.5650.6
44 schema:startDate 2011-10-01T00:00:00Z
45 schema:subjectOf sg:pub.10.1007/s00431-006-0188-y
46 https://doi.org/10.1016/j.trstmh.2006.02.010
47 https://doi.org/10.1128/aac.00014-08
48 https://doi.org/10.1128/aac.02198-16
49 https://doi.org/10.1371/journal.pntd.0005515
50 https://doi.org/10.1517/17425255.4.9.1209
51 schema:url https://clinicaltrials.gov/show/NCT01462500
52 sgo:license sg:explorer/license/
53 sgo:sdDataset clinical_trials
54 rdf:type schema:MedicalStudy
55 Naed2a69d651f4e218f18eaed018bd5a0 schema:name Springer Nature - SN SciGraph project
56 rdf:type schema:Organization
57 anzsrc-for:3053 schema:inDefinedTermSet anzsrc-for:
58 rdf:type schema:DefinedTerm
59 sg:pub.10.1007/s00431-006-0188-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1035417123
60 https://doi.org/10.1007/s00431-006-0188-y
61 rdf:type schema:CreativeWork
62 https://doi.org/10.1016/j.trstmh.2006.02.010 schema:sameAs https://app.dimensions.ai/details/publication/pub.1054751293
63 rdf:type schema:CreativeWork
64 https://doi.org/10.1128/aac.00014-08 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014236737
65 rdf:type schema:CreativeWork
66 https://doi.org/10.1128/aac.02198-16 schema:sameAs https://app.dimensions.ai/details/publication/pub.1062709537
67 rdf:type schema:CreativeWork
68 https://doi.org/10.1371/journal.pntd.0005515 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084622300
69 rdf:type schema:CreativeWork
70 https://doi.org/10.1517/17425255.4.9.1209 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021198914
71 rdf:type schema:CreativeWork
72 https://www.grid.ac/institutes/grid.418350.b schema:Organization
73 https://www.grid.ac/institutes/grid.5650.6 schema:Organization
 




Preview window. Press ESC to close (or click here)


...